Legal

Forward-looking statements.

---

This website contains statements that are forward-looking rather than historical — including statements about NeuroNova’s plans for a US registrational program, its intended indication, its interactions with regulatory authorities, and the possible future development of oral hydralazine for Alzheimer’s disease. Words such as “planned,” “intended,” “will,” and similar expressions identify such statements.

Forward-looking statements involve substantial risks and uncertainties. Actual events and results may differ materially from those expressed or implied, for reasons that include, among others: the inherent uncertainty of pharmaceutical research and development; the outcomes of nonclinical and clinical studies; the timing and outcome of regulatory processes; the company’s ability to obtain the resources required to conduct its program; and competitive, scientific, and economic developments.

Forward-looking statements speak only as of the date they are made. NeuroNova Therapeutics, LLC undertakes no obligation to update any forward-looking statement, except as required by law. No forward-looking statement is a guarantee of future results, and none should be read as a representation that any investigational product will be shown to be safe or effective, or will be approved for marketing, in any jurisdiction.